Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen to provide a business update including discussion of pipeline advancements

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 13, 2022 at 9 a.m. ET, at the 40th J.P. Morgan Healthcare Conference.

A live audio webcast of the presentation will be accessible through Surrozen’s Investor Relations website at An archived edition of the session will be available later that day.

About Surrozen

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit


This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters and depictions that are not historical facts, such as statements relating to claims that the Company’s drug candidates will have certain abilities or application to certain diseases, disorders or conditions; expectations for future growth and profit; forecasts of economic conditions; and the development and commercialization of new drugs or products.

The forward-looking statements contained in this press release reflect the Company’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause actual results to differ significantly from those expressed in any forward-looking statement, including, without limitation: the Company’s ability to discover and develop drug candidates; the Company’s ability to advance SZN-1326, SZN-043, or other future product candidates into, and successfully complete, preclinical studies and clinical studies; and the potential impact, scope and duration of, and the Company’s response to, the COVID-19 pandemic and the potential for recovery from that pandemic. These and other material risks related to the Company’s business are discussed in detail in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and other filings with the U.S. Securities and Exchange Commission. All forward-looking statements included in this document are made only as of the date of this document, and except as otherwise required by applicable law, the Company assumes no obligation to update or disclose revisions to these forward-looking statements.

Media Contact:
Ian Stone, Managing Director
Tel.: (619) 518-3518

Investor Contact:

Primary Logo

Back to news